Antitumor triptycene bisquinones induce a caspase-independent release of mitochondrial cytochrome c and a caspase-2-mediated activation of initiator caspase-8 and -9 in HL-60 cells by a mechanism which does not involve Fas signaling

Anti-Cancer Drugs

Volumn 15, Issue 10, 2004, Pages 929-946

  Perchellet, Elisabeth M ^a   Wang, Yang ^a   Weber, Rebeka L ^a   Lou, Kaiyan ^a   Hua, Duy H ^a   Perchellet, Jean Pierre H ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Caspase; Cytochrome c; Fas; HL 60 cell viability; Triptycene bisquinone

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 2; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; DAUNORUBICIN; DNA FRAGMENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); FAS LIGAND; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; QUINONE DERIVATIVE; TRIPTYCENE 13; TRIPTYCENE 16; TRIPTYCENE 19; TRIPTYCENE 2; TRIPTYCENE 24; TRIPTYCENE 26; TRIPTYCENE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 2; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; CELL SURVIVAL; CYTOCHROMES C; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FAS LIGAND PROTEIN; HL-60 CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; QUINONES;

EID: 9344236552     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200411000-00002     Document Type: Article

References (67)

1. Myers CE, Chabner BA. Anthracyclines. In: Chabner BA, Collins JM (editors): Cancer Chemotherapy: Principles and Practice. Philadelphia, PA: Lippincott; 1990, pp. 356-381.
2. Rossi L, Moore GA, Orrenius S, O'Brien PJ. Quinone toxicity in hepatocytes without oxidative stress. Arch Biochem Biophys 1986; 251:25-35.
3. 2/M cell cycle arrest and apoptosis. Free Rad Biol Med 1998; 24:848-854.
4. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58:351-375.
5. Mimnaugh EG, Kennedy KA, Trush MA, Sinha BK. Adriamycin-enhanced membrane lipid peroxidation in isolated rat nuclei. Cancer Res 1985; 45:3296-3304.
6. Ganapathi R, Grabowski D, Hoeltge G, Neelon R. Modulation of doxorubicin-induced chromosomal damage by calmodulin inhibitors and its relationship to cytotoxicity in progressively doxorubicin-resistant tumor cells. Biochem Pharmacol 1990; 40:1657-1662.
7. Ling YH, Priebe W, Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res 1993; 53:1845-1852.
8. Ramachandran C, You W, Krishan A. Bcl-2 and mdr-1 gene expression during doxorubicin-induced apoptosis in murine P388 and p388/R84 cells. Anticancer Res 1997; 17:3369-3376.
9. Skladanowski A, Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol 1993; 46:375-382.
10. Gamen S, Anel A, Lasierra P, Alava MA, Martinez-Lorenzo MJ, Piñeiro A, et al. Doxorubicin-induced apoptosis in human T-cell leukaemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett 1997; 417:360-364.
11. Côme MG, Skladanowski A, Larsen AK, Laurent G. Dual mechanism of daunorubicin-induced cell death in sensitive and MDR-resistant HL-60 cells. Br J Cancer 1999; 79:1090-1097.
12. 1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells. Cancer Res 2000; 60:1901-1907.
13. Aszalos A, Ladányi A, Bocsi J, Szende B. Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators. Cancer Lett 2001; 167: 157-162.
14. Messner PW, Budihardjo II, Kaufman SH. Chemotherapy-induced apoptosis. Adv Parmacol 1997; 41:461-499.
15. Debatin KM. Activation of apoptosis pathways by anticancer treatment. Toxicol Lett 2000; 112-113:41-48.
16. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256:42-49.
17. Perchellet EM, Magill MJ, Huang X, Brantis CE, Hua DH, Perchellet JP. Triptycenes: a novel synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, induce DNA cleavage and decrease the viability of leukemic cells in the nanomolar range in vitro. Anticancer Drugs 1999; 10:749-766.
18. Wang B, Wu M, Perchellet EM, McIlvain CJ, Sperfslage BJ, Huang X, et al. A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines. Int J Oncol 2001; 19:1169-1178.
19. Hua DH, Tamura M, Huang X, Stephany HA, Helfrich BA, Perchellet EM, et al. Syntheses and bioactivities of substituted 9,10-dihydro-9,10-[1,2] benzenoanthracene-1,4,5,8-tetraones. Unusual reactivities with amines. J Org Chem 2002; 67:2907-2912.
20. Perchellet EM, Sperfslage BJ, Wang Y, Huang X, Tamura M, Hua DH, et al. Among substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8-tetraones, the lead antitumor triptycene bisquinone TT24 blocks nucleoside transport, induces apoptotic DNA fragmentation and decreases the viability of L1210 leukemic cells in the nanomolar range of daunorubicin in vitro. Anticancer Drugs 2002; 13:567-582.
21. Wang B, Perchellet EM, Wang Y, Tamura M, Hua DH, Perchellet JP. Antitumor triptycene bisquinones: a novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities. Anticancer Drugs 2003; 14:503-514.
22. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995; 270:21429-21432.
23. Pommier Y. DNA topoisomerases and their inhibition by anthracyclines. In: Priebe W (editor): Anthracycline Antibiotics. New Analogues, Methods of Delivery, and Mechanisms of Action. Washington, DC: American Chemical Society. ACS Symp Ser 1995; 574:183-203.
24. Kohn KW. Beyond DNA cross-linking: history and prospect of DNA-targeted cancer treatment. Fifteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1996; 56:5533-5546.
25. Li T-K, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001; 41:53-77.
26. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400:83-105.
27. Palumbo M, Gatto B, Moro S, Sissi C, Zagotto G. Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex. Biochim Biophys Acta 2002; 1587:145-154.
28. Topcu Z. DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 2001; 26:405-416.
29. Walker JV, Nitiss JL. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 2002; 20:570-589.
30. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000; 256:12-18.
31. Compton MM. A biochemical hallmark of apoptosis: internucleosomal degradation of the genome. Cancer Metastasis Rev 1992; 11:105-112.
32. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 1997; 75:337-349.
33. Herceg Z, Wang ZQ. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 2001; 477:97-110.
34. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53:3976-3985.
35. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995; 81:801-809.
36. Lazebnik YA, Kaufman SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994; 371:346-347.
37. Kaufmann SH. Proteolytic cleavage during chemotherapy-induced apoptosis. Mol Med Today 1996; 2:298-303.
38. Wang Y, Perchellet EM, Tamura M, Hua DH, Perchellet JP. Induction of poly(ADP-ribose) polymerase-1 cleavage by antitumor triptycene bisquinones in wild-type and daunorubicin-resistant HL-60 cell lines. Cancer Lett 2002; 188:73-83.
39. Hickman JA, Dive C. Apoptosis and Cancer Chemotherapy. Totowa, NJ: Humana Press; 1999.
40. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999; 15:269-290.
41. Perchellet EM, Wang Y, Weber RL, Sperfslage BJ, Lou K, Crossland J, et al. Synthetic 1,4-anthracenedione analogs induce cytochrome c release, caspase-9, -3, and -8 activities, poly(ADP-ribose) polymerase-1 cleavage and internucleosomal DNA fragmentation in HL-60 cells by a mechanism which involves caspase-2 activation but not Fas signaling. Biochem Pharmacol 2004; 67:523-537.
42. Marquardt D, McCrone S, Center MS. Mechanisms of multidrug resistance in HL-60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 1990; 50:1426-1430.
43. Cory AH, Owen JC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991; 3:207-212.
44. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86:147-157.
45. Wu M, Wang B, Perchellet EM, Sperfslage BJ, Stephany HA, Hua DH, et al. Synthetic 1,4-anthracenediones, which block nucleoside transport and induce DNA fragmentation, retain their cytotoxicity in daunorubicin-resistant HL-60 cell lines. Anticancer Drugs 2001; 12:807-819.
46. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91:479-489.
47. Powis G. Free radical formation by antitumor quinones. Free Rad Biol Med 1989;6:63-101.
48. Monks TJ, Hanzlik RP, Cohen GM, Ross D, Graham DG. Quinone chemistry and toxicity. Toxicol Appl Pharmacol 1992; 112:2-16.
49. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. Bcl-2 protein inhibits etopside-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993; 53:4251-4256.
50. Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 2000; 60:7133-7141.
51. Notarbartolo M, Cervello M, Dusonchet L, Cusimano A, D'Alessandro N. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factor IAP (inhibitory of apoptosis proteins). Cancer Lett 2002; 180:91-101.
52. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, et al. Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukaemia cells. Cancer Res 1997; 57:3331-3334.
53. McGahon AJ, Costa PA, Daly L, Cotter TG. Chemotherapeutic drug-induced apoptosis in human leukemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol 1998; 101:539-547.
54. Tolomeo M, Dusonchet I, Meli M, Grimaudo S, D'Alessandro N, Papoff G, et al. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ 1998; 5:735-742.
55. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94:491-501.
56. Scaffidi CA, Fulda S, Srinivasan A, Friesen C, Li F, Feng L, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17:1675-1687.
57. Kuwana T, Smith JJ, Muzio M, Dixit V, Newmeyer DD, Kornbluth S. Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. J Biol Chem 1998; 273:16589-16594.
58. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, et al. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 1998; 273:33942-33948.
59. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, Hernández G, Rodríguez A, López-Rivas A, et al. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 2002; 277:10883-10892.
60. Kim SG, Ravi G, Hoffmann C, Jung YP, Kim M, Chen A, et al. p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, C1-IB-MECA. Biochem Pharmacol 2002; 63:871-880.
61. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 1985; 82:790-794.
62. Gimonet D, Landais E, Bobichon H, Coninx P, Liautaud-Roger F. Induction of apoptosis by bleomycin in p53-null HL-60 leukemia cells. Int J Oncol 2004; 24:313-319.
63. Kim JS, Lee JM, Chwae Y-J, Kim YH, Lee JH, Kim K, et al. Cisplatin-induced apoptosis in Hep3B cells: mitochondria-dependent and -independent pathways. Biochem Pharmacol 2004; 67:1459-1468.
64. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002; 297:1352-1354.
65. Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S. Distinct pathways for stimulation of cytochrome c release. J Biol Chem 2000; 275:32438-32443.
66. Robertson JD, Enoksson M, Suomela M, Zhivotovsky B, Orrenius S. Capase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem 2002; 277:29803-29809.
67. Sien XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 1999; 274:5053-5060.